User login

We offer our registered users tailored information, free online courses and exclusive content.

You have an old EXCEMED account ...

Our platform has been renewed. All users registered at any of the old websites are kindly requested to reset their password. Why is this?

... or you lost your password?

Recommended reading

This section contains a list of publications that our Scientific Committee Members consider to be valuable for anyone wishing to learn more about specific aspects of diabetes.

The list is continually updated, so do check back frequently. If you have suggestions for important papers to be included, please email us: info@excemed.org


Education in diabetes

  1. National standards for diabetes self-management education and support. Haas L, Maryniuk M, Beck J, Cox CE, Duker P, Edwards L, Fisher EB, Hanson L, Kent D, Kolb L, McLaughlin S, Orzeck E, Piette JD, Rhinehart AS, Rothman R, Sklaroff S, Tomky D, Youssef G; 2012 Standards Revision Task Force. Diabetes Care. 2014;37 Suppl 1:S144-53.
  2. Increasing diabetes educators' confidence in physical activity and exercise counselling: the effectiveness of the "physical activity and exercise toolkit" training intervention. Shields CA, Fowles JR, Dunbar P, Barron B, McQuaid S, Dillman CJ. Can J Diabetes. 2013 Dec;37(6):381-7.
  3. A new dawn: The role of social media in diabetes education. Cooper A, Kar P. Journal of Diabetes Nursing . 2014, Vol. 18 Issue 2, p68-71.Anchor


Physiopathology of diabetes and its complications

  1. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Kahn SE, Cooper ME, Del Prato S. Lancet. 2014 Mar 22;383(9922):1068-83.
  2. The importance of the cellular stress response in the pathogenesis and treatment of type 2 diabetes. Hooper PL, Balogh G, Rivas E, Kavanagh K, Vigh L. Cell Stress Chaperones. 2014 Feb 13.
  3. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study. Bianchi C, Miccoli R, Trombetta M, Giorgino F, Frontoni S, Faloia E, Marchesini G, Dolci MA, Cavalot F, Cavallo G, Leonetti F, Bonadonna RC, Del Prato S; GENFIEV Investigators. J Clin Endocrinol Metab. 2013 May;98(5):2100-5.
  4. Prediction of diabetes based on baseline metabolic characteristics in individuals at high risk. Defronzo RA, Tripathy D, Schwenke DC, Banerji M, Bray GA, Buchanan TA, Clement SC, Henry RR, Kitabchi AE, Mudaliar S, Ratner RE, Stentz FB, Musi N, Reaven PD, Gastaldelli A; ACT NOW Study. Diabetes Care. 2013 Nov;36(11):3607-12.
  5. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab. 2013;18(3):333-40. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, Kharitonenkov A, Bumol T, Schilske HK, Moller DE.
  6. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group. N Engl J Med. 2015;373(3):232-42. Link to PubMed http://www.ncbi.nlm.nih.gov/pubmed/26052984
  7. The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes. Whalen K, Miller S, Onge ES. Clin Ther. 2015;37(6):1150-66. Link to PubMed http://www.ncbi.nlm.nih.gov/pubmed/25891804
  8. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, McCarren M, Duckworth WC, Emanuele NV; VADT Investigators. N Engl J Med. 2015;372(23):2197-206. Link to PubMed http://www.ncbi.nlm.nih.gov/pubmed/26039600

 

Obesity and its Comorbities

  1. Body-mass index and mortality among adults with incident type 2 diabetes. Tobias DK, Pan A, Jackson CL, O'Reilly EJ, Ding EL, Willett WC, Manson JE, Hu FB. N Engl J Med. 2014 Jan 16;370(3):233-44.
  2. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. Courcoulas AP, Christian NJ, Belle SH, Berk PD, Flum DR, Garcia L, Horlick M, Kalarchian MA, King WC, Mitchell JE, Patterson EJ, Pender JR, Pomp A, Pories WJ, Thirlby RC, Yanovski SZ, Wolfe BM; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. JAMA. 2013 Dec 11;310(22):2416-25.
  3. Body mass and weight change in adults in relation to mortality risk. Adams KF, Leitzmann MF, Ballard-Barbash R, Albanes D, Harris TB, Hollenbeck A, Kipnis V. Am J Epidemiol. 2014 Jan 15;179(2):135-44.
  4. Intensive weight loss intervention in older individuals: results from the Action for Health in Diabetes Type 2 diabetes mellitus trial. Espeland MA, Rejeski WJ, West DS, Bray GA, Clark JM, Peters AL, Chen H, Johnson KC, Horton ES, Hazuda HP; Action for Health in Diabetes Research Group. J Am Geriatr Soc. 2013 Jun;61(6):912-22.
  5. Metabolic complications of obesity. Pedersen SD. Best Pract Res Clin Endocrinol Metab. 2013 Apr;27(2):179-93Anchor


Possible complications of diabetic treatment

  1. Perspective: SGLT2 inhibitors may predispose to ketoacidosis. Taylor SI, Blau JE, Rother KI. J Clin Endocrinol Metab. 2015 Jun 18:jc20151884. [Epub ahead of print]. Link to PubMed http://www.ncbi.nlm.nih.gov/pubmed/26086329
  2. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Diabetes Care. 2015 Jun 15. pii: dc150843. [Epub ahead of print]. Link to PubMed http://www.ncbi.nlm.nih.gov/pubmed/26078479


Practical management of diabetic treatment

  1. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators. N Engl J Med. 2013 Oct 3;369(14):1317-26
  2. Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison. Craddy P, Palin HJ, Johnson KI. Diabetes Ther. 2014 Mar 25.
  3. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Bailey CJ, Aschner P, Del Prato S, LaSalle J, Ji L, Matthaei S; Global Partnership for Effective Diabetes Management. Diab Vasc Dis Res. 2013 Sep;10(5):397-409.
  4. 2013 ESC/EASD guidelines on the management of diabetes and cardiovascular disease: Established knowledge and evidence gaps. Paneni F. Diab Vasc Dis Res. 2014 Jan;11(1):5-10.
  5. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. DeFronzo RA, Eldor R, Abdul-Ghani M. Diabetes Care. 2013 Aug;36 Suppl 2:S127-38.Anchor

 

Global diabetes and obesity epidemics

  1. Global estimates of diabetes prevalence for 2013 and projections for 2035. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Diabetes Res Clin Pract. 2014 Feb;103(2):137-49.